We have products that are clearly differentiated ... at Sanofi since 2018 and is currently the medical director for Sanofi Genzyme UK & IE. He is an experienced pharmaceutical physician whose ...

Sanofi's Genzyme rare diseases division already sells ... but the Committee for Medicinal Products for Human Use (CHMP) said in its positive opinion that the drug was not deemed to be a new ...

Strategic Collaborations: The company's ability to establish and maintain collaborations, such as the prior agreement with ...

Sanofi-Genzyme, and Valeo Pharma. The purpose of the non-promotional symposium was for disease state awareness and is not meant to imply the efficacy or safety of any AstraZeneca products or other ...

Prior to joining BioAffinity in 2016 as SVP of R&D, he was associate director of science at Genzyme, now part of Sanofi. Bausta held a similar position at Ilex Products. He replaces Vivienne Rebel, ...

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

Sanofi (Symbol: SNY) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.